Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2013 1
2014 3
2015 1
2017 2
2020 1
2021 5
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience.
Chiron R, Hoefsloot W, Van Ingen J, Marchandin H, Kremer L, Morisse-Pradier H, Charriot J, Mallet JP, Herrmann JL, Caimmi D, Moreau J, Dumont Y, Godreuil S, Bergeron A, Drevait M, Bouzat-Rossigneux E, Terrail N, Andrejak C, Veziris N, Grenet D, Coudrat A, Catherinot E. Chiron R, et al. Open Forum Infect Dis. 2022 Sep 11;9(10):ofac465. doi: 10.1093/ofid/ofac465. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36267258 Free PMC article.
We also assessed the association of patient drug compliance with culture conversion and clinical outcomes. RESULTS: Twenty-six patients had long-term follow-up data available. Culture conversion was achieved in 54% (14/26) of the patients with no difference between CF and …
We also assessed the association of patient drug compliance with culture conversion and clinical outcomes. RESULTS: Twenty-six patients had …
[National consensus regarding azithromycin use in cystic fibrosis].
Abely M, Jubin V, Bessaci-Kabouya K, Chiron R, Bui S, Fayon M. Abely M, et al. Among authors: chiron r. Rev Mal Respir. 2015 Jun;32(6):557-65. doi: 10.1016/j.rmr.2014.10.733. Epub 2015 May 21. Rev Mal Respir. 2015. PMID: 26003196 Review. French.
RESULTS: Thirty identified French CF centers participated in the process on 49 (61%), which comprised 3 rounds. Experts validated azithromycin as a long-term anti-inflammatory agent in children aged over 6 years, presenting with the classical form of CF, irrespective of th …
RESULTS: Thirty identified French CF centers participated in the process on 49 (61%), which comprised 3 rounds. Experts validated azithromyc …
Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.
Menetrey Q, Sorlin P, Jumas-Bilak E, Chiron R, Dupont C, Marchandin H. Menetrey Q, et al. Among authors: chiron r. Genes (Basel). 2021 Apr 21;12(5):610. doi: 10.3390/genes12050610. Genes (Basel). 2021. PMID: 33919046 Free PMC article. Review.
An inexorable colonization by bacteria of both endogenous and environmental origin is observed in most patients, leading to a vicious cycle of infection-inflammation. In this context, long-term colonization together with competitive interactions among bacteria can lead to …
An inexorable colonization by bacteria of both endogenous and environmental origin is observed in most patients, leading to a vicious cycle …
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Lemonnier L, Burnet E, Paillasseur JL, Da Silva J, Burgel PR. Martin C, et al. Among authors: chiron r. J Cyst Fibros. 2022 May;21(3):489-496. doi: 10.1016/j.jcf.2022.01.012. Epub 2022 Feb 2. J Cyst Fibros. 2022. PMID: 35123901
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the indication for lung transplantation. Yet no long-term data is available in lung transplant can …
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary …
First Wave of COVID-19 in French Patients with Cystic Fibrosis.
Corvol H, de Miranda S, Lemonnier L, Kemgang A, Reynaud Gaubert M, Chiron R, Dalphin ML, Durieu I, Dubus JC, Houdouin V, Prevotat A, Ramel S, Revillion M, Weiss L, Guillot L, Boelle PY, Burgel PR. Corvol H, et al. Among authors: chiron r. J Clin Med. 2020 Nov 10;9(11):3624. doi: 10.3390/jcm9113624. J Clin Med. 2020. PMID: 33182847 Free PMC article.
Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were discharged home without noticeable short-term sequelae. Overall, French CF patients were rarely diagnosed with COVID-19. Further res …
Ten developed complications (including acute respiratory distress syndrome in two post-lung transplant patients), but all recovered and were …
Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
Mazurek H, Chiron R, Kucerova T, Geidel C, Bolbas K, Chuchalin A, Blanco-Aparicio M, Santoro D, Varoli G, Zibellini M, Cicirello HG, Antipkin YG. Mazurek H, et al. Among authors: chiron r. Pediatr Pulmonol. 2014 Nov;49(11):1076-89. doi: 10.1002/ppul.22989. Epub 2014 Jan 24. Pediatr Pulmonol. 2014. PMID: 24464974 Clinical Trial.
The primary endpoint of the core phase was to demonstrate the non-inferiority of TNS4 compared to TNS5 in terms of absolute change from baseline to week 4 in FEV(1) % predicted. The assessment of long-term safety was the primary purpose of the extension phase. Throughout a …
The primary endpoint of the core phase was to demonstrate the non-inferiority of TNS4 compared to TNS5 in terms of absolute change from base …
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Among authors: chiron r. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventil

…

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence

…
Integrated care pathways for airway diseases (AIRWAYS-ICPs).
European Innovation Partnership on Active and Healthy Ageing, Action Plan B3; Mechanisms of the Development of Allergy, WP 10; Global Alliance against Chronic Respiratory Diseases; Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, Annesi-Maesano I, Anto JM, Bachert C, Baena-Cagnani CE, Bai C, Baigenzhin A, Barbara C, Barnes PJ, Bateman ED, Beck L, Bedbrook A, Bel EH, Benezet O, Bennoor KS, Benson M, Bernabeu-Wittel M, Bewick M, Bindslev-Jensen C, Blain H, Blasi F, Bonini M, Bonini S, Boulet LP, Bourdin A, Bourret R, Bousquet PJ, Brightling CE, Briggs A, Brozek J, Buhl R, Bush A, Caimmi D, Calderon M, Calverley P, Camargos PA, Camuzat T, Canonica GW, Carlsen KH, Casale TB, Cazzola M, Cepeda Sarabia AM, Cesario A, Chen YZ, Chkhartishvili E, Chavannes NH, Chiron R, Chuchalin A, Chung KF, Cox L, Crooks G, Crooks MG, Cruz AA, Custovic A, Dahl R, Dahlen SE, De Blay F, Dedeu T, Deleanu D, Demoly P, Devillier P, Didier A, Dinh-Xuan AT, Djukanovic R, Dokic D, Douagui H, Dubakiene R, Eglin S, Elliot F, Emuzyte R, Fabbri L, Fink Wagner A, Fletcher M, Fokkens WJ, Fonseca J, Franco A, Frith P, Furber A, Gaga M, Garcés J, Garcia-Aymerich J, Gamkrelidze A, Gonzales-Diaz S, Gouz… See abstract for full author list ➔ European Innovation Partnership on Active and Healthy Ageing, Action Plan B3, et al. Among authors: chiron r. Eur Respir J. 2014 Aug;44(2):304-23. doi: 10.1183/09031936.00014614. Epub 2014 Jun 12. Eur Respir J. 2014. PMID: 24925919 Free article.
AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiati …
AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) pro …
15 results